Evidence map›Paper›PMID 38774946›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

Rare Earth Nanoprobes for Targeted Delineation of Triple Negative Breast Cancer and Enhancement of Radioimmunotherapy.

Zi-He Ming, Yong-Qu Zhang, Liang Song, Min Chen, Lin-Ling Lin, Yue-Yang He, Wan-Ling Liu, Yuan-Yuan Zhu, Yun Zhang, Guo-Jun Zhang

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zi-He MingCancer Center and Department of Breast and Thyroid Surgery, Xiang'an Hospital of Xiamen University School of Medicine, Xiamen University, Xiamen, Fujian, 361104, China.ORCID 0009-0005-5643-2907
Yong-Qu ZhangDepartment of Breast Center, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, 515041, China.
Liang SongState Key Laboratory of Structural Chemistry, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou, Fujian, 350000, China.
Min ChenFujian Key Laboratory of Precision Diagnosis and Treatment in Breast Cancer, Xiang'an Hospital of Xiamen University, Xiamen, Fujian, 361102, China.
Lin-Ling LinCancer Center and Department of Breast and Thyroid Surgery, Xiang'an Hospital of Xiamen University School of Medicine, Xiamen University, Xiamen, Fujian, 361104, China.
Yue-Yang HeCancer Center and Department of Breast and Thyroid Surgery, Xiang'an Hospital of Xiamen University School of Medicine, Xiamen University, Xiamen, Fujian, 361104, China.
Wan-Ling LiuCancer Center and Department of Breast and Thyroid Surgery, Xiang'an Hospital of Xiamen University School of Medicine, Xiamen University, Xiamen, Fujian, 361104, China.
Yuan-Yuan ZhuCancer Center and Department of Breast and Thyroid Surgery, Xiang'an Hospital of Xiamen University School of Medicine, Xiamen University, Xiamen, Fujian, 361104, China.
Yun ZhangState Key Laboratory of Structural Chemistry, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou, Fujian, 350000, China.ORCID 0000-0001-6288-4671
Guo-Jun ZhangCancer Center and Department of Breast and Thyroid Surgery, Xiang'an Hospital of Xiamen University School of Medicine, Xiamen University, Xiamen, Fujian, 361104, China.ORCID 0000-0001-5182-5887

Funding

Fujian Major Scientific and Technological Special Project for Social Development 2020YZ016002Fujian Science and Technology Innovation Laboratory for Optoelectronic Information of China 2020ZZ114Guangdong Basic and Applied Basic Research Foundation 2024A1515011271National Natural Science Foundation of China 32171363National Natural Science Foundation of China 62105333National Natural Science Foundation of China 82172009Start-up fund from the Third Affiliated Hospital of Kunming Medical University ZC0024Young Elite Scientist Sponsorship Program by CAST YESS20210116
6 · The paper itself

Abstract

Radiotherapy demonstrates a synergistic effect with immunotherapy by inducing a transformation of "immune cold" tumors into "immune hot" tumors in triple negative breast cancer (TNBC). Nevertheless, the effectiveness of immunotherapy is constrained by low expression of tumor-exposed antigens, inadequate inflammation, and insufficient tumor infiltrating lymphocyte (TILs). To address this predicament, novel lutecium-based rare earth nanoparticles (RENPs) are synthesized with the aim of amplifying radiation effect and tumor immune response. The nanoprobe is characterized by neodymium-based down-conversion fluorescence, demonstrating robust photostability, biocompatibility, and targetability. The conjugation of RENPs with a CXCR4 targeted drug enables precise delineation of breast tumors using a near-infrared imaging system and improves radiation efficacy via lutetium-based radio-sensitizer in vivo. Furthermore, the study shows a notable enhancement of immune response through the induction of immunogenic cell death and recruitment of TILs, resulting in the inhibition of tumor progression both in vitro and in vivo models following the administration of nanoparticles. Hence, the novel multifunctional nanoprobes incorporating various lanthanide elements offer the potential for imaging-guided tumor delineation, radio-sensitization, and immune activation post-radiation, thus presenting an efficient radio-immunotherapeutic approach for TNBC.

Indexed as

NanoparticlesRadioimmunotherapyTriple Negative Breast NeoplasmsAnimalsCell Line, TumorDisease Models, AnimalFemaleHumansMetals, Rare EarthMiceMetals, Rare Earthradioimmunotherapyradiosensitizationrare‐earth nanoparticlessecond near‐infrared‐fluorescence imagingtriple negative breast cancer

Identifiers

PMID38774946
PMCPMC11304243

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.